Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LK101 Combined With PD-1 or PD-L1 Monoclonal Antibody in Lung Cancer
NCT05886439Phase 2Recruiting
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Start
- May 2023
- Primary completion
- May 2027
- Modality
- Whole Cell Cancer Vaccines, Dendritic Cell Vaccines, mRNA Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of LK101 in non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC) (3 arms), sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences. Primary endpoints: Dose-Limiting Toxicity, Adverse Events and 2 more. Started May 2023; status: recruiting.
02
Drugs
LK101
03
Conditions
non-small cell lung cancer (NSCLC)small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT05886439.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05886439.